These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2545750

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
    Ostlere LS, Mallett RB, Kaminski A, Kaminski ER, Pereira RS, Holden CA.
    Br J Dermatol; 1995 Jul; 133(1):1-5. PubMed ID: 7669618
    [Abstract] [Full Text] [Related]

  • 23. Disordered cyclic nucleotide metabolism--a basic defect in atopic dermatitis.
    Butler JM.
    Australas J Dermatol; 1984 Apr; 25(1):3-7. PubMed ID: 6205650
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis.
    Gregurek-Novak T.
    J Eur Acad Dermatol Venereol; 2001 Jan; 15(1):81-2. PubMed ID: 11451336
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Atopic dermatitis: a defect of intracellular secondary messenger systems?
    Holden CA.
    Clin Exp Allergy; 1990 Mar; 20(2):131-6. PubMed ID: 2162724
    [Abstract] [Full Text] [Related]

  • 29. Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes.
    Li SH, Chan SC, Kramer SM, Hanifin JM.
    J Interferon Res; 1993 Jun; 13(3):197-202. PubMed ID: 8396165
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition.
    Chan SC, Li SH, Hanifin JM.
    J Invest Dermatol; 1993 May; 100(5):681-4. PubMed ID: 8388009
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis.
    Kanda N, Enomoto U, Watanabe S.
    J Invest Dermatol; 2001 Dec; 117(6):1635-46. PubMed ID: 11886533
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of non-steroidal ointment therapy for adult type atopic dermatitis: inquiry analysis on clinical effect.
    Katayama I, Taniguchi H, Matsunaga T, Yokozeki H, Nishioka K.
    J Dermatol Sci; 1997 Jan; 14(1):37-44. PubMed ID: 9049806
    [Abstract] [Full Text] [Related]

  • 35. Regulation by a beta-adrenergic receptor of a Ca2+-independent adenosine 3',5'-(cyclic)monophosphate phosphodiesterase in C6 glioma cells.
    Onali P, Schwartz JP, Hanbauer I, Costa E.
    Biochim Biophys Acta; 1981 Jul; 675(2):285-92. PubMed ID: 6268187
    [Abstract] [Full Text] [Related]

  • 36. Direct evidence for extracellular adenosine 3':5'-monophosphate phosphodiesterase induction and phosphodiesterase inhibitor repression by exogenous adenosine 3':5'-monophosphate in Dictyostelium purpureum.
    Tsang AS, Coukell MB.
    Eur J Biochem; 1979 Apr 02; 95(2):419-25. PubMed ID: 222584
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.
    Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Paller AS, Stevens SR, Whitaker-Worth DL, Tong KB.
    J Am Acad Dermatol; 2003 Apr 02; 48(4):553-63. PubMed ID: 12664019
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
    Hiyama H, Arichika N, Okada M, Koyama N, Tahara T, Haruta J.
    J Pharmacol Exp Ther; 2023 Jul 02; 386(1):45-55. PubMed ID: 37041087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.